Literature DB >> 15968266

A clinician's paradigm in the treatment of atopic dermatitis.

William Abramovits1.   

Abstract

Successful management of atopic dermatitis requires a multipronged approach that includes skin barrier function care, use of topical or systemic agents, and identification and elimination of precipitating or exacerbating factors. Because the origin of atopic dermatitis is multifactorial and trigger factors differ among patients, treatment plans must be specific to the individual patient. This article offers an example of a permutational, or flexible, treatment paradigm. The approach utilizes 4 topical regimens--high-potency topical corticosteroids, lowest effective potency topical corticosteroids, topical calcineurin inhibitors (TCIs), or topical corticosteroid/TCI combinations--as initial therapy in a variety of induction protocols, as determined by the severity of a patient's condition and history. The paradigm permits treatment to progress from a chosen induction therapy to maintenance therapy. During the patient's induction therapy, as soon as an acceptable level of clearance is achieved, therapy should be adjusted to a maintenance regimen, such as monotherapy with either a TCI or a lowest effective potency topical corticosteroid (the latter used intermittently) or an alternation of the two agents. If there is no clearance or positive response with the initial induction protocol, the clinician should move to one of the alternative regimens.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15968266     DOI: 10.1016/j.jaad.2005.04.032

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  6 in total

1.  The aryl hydrocarbon receptor AhR links atopic dermatitis and air pollution via induction of the neurotrophic factor artemin.

Authors:  Takanori Hidaka; Eisaku Ogawa; Eri H Kobayashi; Takafumi Suzuki; Ryo Funayama; Takeshi Nagashima; Taku Fujimura; Setsuya Aiba; Keiko Nakayama; Ryuhei Okuyama; Masayuki Yamamoto
Journal:  Nat Immunol       Date:  2016-11-21       Impact factor: 25.606

2.  Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies.

Authors:  Lawrence F Eichenfield; Wynnis L Tom; Timothy G Berger; Alfons Krol; Amy S Paller; Kathryn Schwarzenberger; James N Bergman; Sarah L Chamlin; David E Cohen; Kevin D Cooper; Kelly M Cordoro; Dawn M Davis; Steven R Feldman; Jon M Hanifin; David J Margolis; Robert A Silverman; Eric L Simpson; Hywel C Williams; Craig A Elmets; Julie Block; Christopher G Harrod; Wendy Smith Begolka; Robert Sidbury
Journal:  J Am Acad Dermatol       Date:  2014-05-09       Impact factor: 11.527

3.  Treatment of Atopic Dermatitis From the Perspective of Traditional Persian Medicine: Presentation of a Novel Therapeutic Approach.

Authors:  Rasool Choopani; Mehrzad Mehrbani; Alireza Fekri; Mitra Mehrabani
Journal:  J Evid Based Complementary Altern Med       Date:  2015-08-09

Review 4.  The role of antiseptic agents in atopic dermatitis.

Authors:  Melissa Lee; Hugo Van Bever
Journal:  Asia Pac Allergy       Date:  2014-10-29

5.  Clinical utility of clocortolone pivalate for the treatment of corticosteroid-responsive skin disorders: a systematic review.

Authors:  Sanjay Singh; Baldeep Kaur Mann
Journal:  Clin Cosmet Investig Dermatol       Date:  2012-06-22

6.  Haplopine Ameliorates 2,4-Dinitrochlorobenzene-Induced Atopic Dermatitis-Like Skin Lesions in Mice and TNF-α/IFN-γ-Induced Inflammation in Human Keratinocyte.

Authors:  Tae-Young Kim; Ye Jin Kim; Jonghwan Jegal; Beom-Geun Jo; Han-Seok Choi; Min Hye Yang
Journal:  Antioxidants (Basel)       Date:  2021-05-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.